EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Characterization of NAT , GST , and CYP2E1 Genetic Variation in Sub‐Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases

Thandeka V B Malinga iD, Houcemeddine Othman iD, Maria Paximadis iD, Caroline T Tiemessen iD, Michèle Ramsay iD, Scott Hazelhurst iD, David Twesigomwe iD

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Thandeka V B Malinga und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Hauptthemen laut MEDLINE: Antitubercular Agents, Arylamine N-Acetyltransferase, Cytochrome P-450 CYP2E1, Glutathione Transferase. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHGRI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) is a major health burden in Africa. Although TB is treatable, anti‐TB drugs are associated with adverse drug reactions (ADRs), which are partly attributed to pharmacogenetic variation. The distribution of star alleles (haplotypes) influencing anti‐TB drug metabolism is unknown in many African populations. This presents challenges in implementing genotype‐guided therapy in Africa to decrease the occurrence of ADRs and enhance the efficacy of anti‐TB drugs. In this study, we used StellarPGx to call variants and star alleles in NAT1 , NAT2 , GSTM1 , GSTT1 , GSTP1 , and CYP2E1 , from 1079 high‐depth African whole genomes. We present the distribution of common, rare, and potential novel star alleles across various Sub‐Saharan African (SSA) populations, in comparison with other global populations. NAT1*10 (53.6%), GSTT1*0 (65%), GSTM1*0 (48%), and NAT2*5 (17.5%) were among the predominant functionally relevant star alleles. Additionally, we predicted varying phenotype distributions for NAT1 and NAT2 (acetylation) and the glutathione‐S‐transferase (GST) enzymes (detoxification activity) between SSA and other global populations. Forty‐seven potentially novel haplotypes were identified computationally across the genes. This study provides insight into the distribution of key variants and star alleles potentially relevant to anti‐TB drug metabolism and other drugs prescribed across various African populations. The high number of potentially novel star alleles exemplifies the need for pharmacogenomics studies in the African context. Overall, our study provides a foundation for functional pharmacogenetic studies and potential implementation of pharmacogenetic testing in Africa to reduce the risk of ADRs related to treatment of TB and other diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsArylamine N-AcetyltransferaseCytochrome P-450 CYP2E1Glutathione TransferaseSub-Saharan African PeopleTuberculosisHumansAfrica South of the SaharaAllelesGenetic VariationHaplotypesPharmacogeneticsPharmacogenomic Variants

Substanzen

Antitubercular AgentsArylamine N-AcetyltransferaseCytochrome P-450 CYP2E1Glutathione TransferaseNAT2 protein, human

Autor:innen und Institutionen

  • Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Division of Human Genetics, National Health Laboratory Service, and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Laboratory of Cytogenetics, Molecular Genetics and Reproductive Biology (LR03SP02), Farhat Hached University Hospital, Sousse, Tunisia.
  • School of Molecular and Cell Biology, Faculty of Science, University of the Witwatersrand, Johannesburg, South Africa.
  • Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • School of Electrical and Information Engineering, University of the Witwatersrand, Johannesburg, South Africa.

ORCID-Profile: Thandeka V B Malinga, Houcemeddine Othman, Maria Paximadis, Caroline T Tiemessen, Michèle Ramsay, Scott Hazelhurst, David Twesigomwe

Förderung

  • NHGRI NIH HHS

Zitieren

APA

Malinga, T. V. B., Othman, H., Paximadis, M., Tiemessen, C. T., Ramsay, M., Hazelhurst, S., & Twesigomwe, D. (2025). Characterization of NAT , GST , and CYP2E1 Genetic Variation in Sub‐Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3557

Vancouver

Malinga TVB, Othman H, Paximadis M, Tiemessen CT, Ramsay M, Hazelhurst S, et al. Characterization of NAT , GST , and CYP2E1 Genetic Variation in Sub‐Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3557

BibTeX
@article{Malinga2025,
  author = {Malinga, Thandeka V B and Othman, Houcemeddine and Paximadis, Maria and Tiemessen, Caroline T and Ramsay, Michèle and Hazelhurst, Scott and Twesigomwe, David},
  title = {Characterization of NAT , GST , and CYP2E1 Genetic Variation in Sub‐Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3557}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche